Fig. 3
From: VWCE as a potential biomarker associated with immune infiltrates in breast cancer
The relationship between VWCE expression and the clinical characteristics of breast cancer patients. A: ER status (ER−, ER+), B: PR status (PR−, PR +), C: HER2 status (HER2+, HER2−), D: age (> 21 ≤ 40, > 40 ≤ 70, and > 70 ≤ 97), E: nodal status (N−, N+). F: subtypes (Basal-like, HER2-E, Luminal A, Luminal B, and normal basal-like)